About neurovance

This author has not yet filled in any details.
So far neurovance has created 18 blog entries.

Neurovance Announces Agreement to be Acquired by Otsuka Pharmaceutical

March 2nd, 2017|

Otsuka Pharmaceutical to Acquire Neurovance, Inc.

March 2nd, 2017|

Neurovance Announces Appointment of Brian Goff as COO as the Company Prepares for the Next Stage of Growth and Development

December 14th, 2016|

Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials

July 27th, 2016|

Neurovance Appoints Jeff Bailey to Chair Its Board of Directors

January 7th, 2016|

Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD

January 7th, 2016|

Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential for Centanafadine Compared to Stimulants Used for Adult ADHD

December 11th, 2014|

Neurovance Completes Enrollment in Human Abuse Liability Study for Centanafadine (Formerly Called EB-1020) for Adult ADHD

August 7th, 2014|

Neurovance Appoints Brigitte Robertson, MD, Vice President, Clinical Development

August 5th, 2014|

Neurovance’s Lead Product Granted Non-Proprietary Name; EB-1020 SR Now Called Centanafadine SR

June 11th, 2014|